|
1
|
Bolli N, Avet-Loiseau H, Wedge DC, Van Loo
P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S,
Bignell GR, et al: Heterogeneity of genomic evolution and
mutational profiles in multiple myeloma. Nat Commun. 5:29972014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moreau P, San Miguel J, Sonneveld P,
Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA,
Ludwig H, Einsele H, et al ESMO Guidelines Committee, : Multiple
myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 28 (Suppl_4):iv52–iv61. 2017. View Article : Google Scholar
|
|
3
|
Mateos MV, Dimopoulos MA, Cavo M, Suzuki
K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, et al
ALCYONE Trial Investigators, : Daratumumab plus bortezomib,
melphalan, and prednisone for untreated myeloma. N Engl J Med.
378:518–528. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rodriguez TE, Hari P, Stiff PJ, Smith SE,
Sterrenberg D and Vesole DH: Busulfan, melphalan, and bortezomib
versus high-dose melphalan as a conditioning regimen for autologous
hematopoietic stem cell transplantation in multiple myeloma. Biol
Blood Marrow Transplant. 22:1391–1396. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ocio EM, Richardson PG, Rajkumar SV,
Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D,
Niesvizky R, et al: New drugs and novel mechanisms of action in
multiple myeloma in 2013: A report from the International Myeloma
Working Group (IMWG). Leukemia. 28:525–542. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stewart AK, Rajkumar SV, Dimopoulos MA,
Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS,
Mihaylov GG, et al ASPIRE Investigators, : Carfilzomib,
lenalidomide, and dexamethasone for relapsed multiple myeloma. N
Engl J Med. 372:142–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian J, He H and Lei G: Wnt/β-catenin
pathway in bone cancers. Tumour Biol. 35:9439–9445. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Savvidou I, Khong T, Cuddihy A, McLean C,
Horrigan S and Spencer A: β-catenin inhibitor BC2059 is efficacious
as monotherapy or in combination with proteasome inhibitor
bortezomib in multiple myeloma. Mol Cancer Ther. 16:1765–1778.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Palumbo A, Chanan-Khan A, Weisel K, Nooka
AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV,
et al CASTOR Investigators, : Daratumumab, bortezomib, and
dexamethasone for multiple myeloma. N Engl J Med. 375:754–766.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qiang YW, Heuck CJ, Shaughnessy JD Jr,
Barlogie and Epstein J: Proteasome inhibitors and bone disease.
Semin Hematol. 49:243–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vergara-Ortega DN, Sevilla-Reyes EE,
Herrera-Ortiz A, Torres-Ibarra L, Salmerón J, Lazcano-Ponce E and
Sánchez- Alemán MA: Real time PCR to evaluate HSV-2 shedding from
anal and genital samples among men who have sex with men, living
with HIV. J Med Virol. 90:745–752. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fairfield H, Falank C, Avery L and Reagan
MR: Multiple mye-loma in the marrow: Pathogenesis and treatments.
Ann N Y Acad Sci. 1364:32–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dimopoulos K, Gimsing P and Grønbæk K: The
role of epigenetics in the biology of multiple myeloma. Blood
Cancer J. 4:e2072014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saki N, Abroun S, Hajizamani S, Rahim F
and Shahjahani M: Asso-ciation of chromosomal translocation and
miRNA expression with the pathogenesis of multiple myeloma. Cell J.
16:99–110. 2014.PubMed/NCBI
|
|
15
|
Nijhof IS, Groen RWJ, Noort WA, van Kessel
B, de Jong-Korlaar R, Bakker J, van Bueren JJ, Parren PW, Lokhorst
HM, van de Donk NW, et al: Preclinical evidence for the therapeutic
potential of CD38-targeted immuno-chemotherapy in multiple myeloma
patients refractory to lenalidomide and bortezomib. Clin Cancer
Res. 21:2802–2810. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grövdal M, Nahi H, Gahrton G, Liwing J,
Waage A, Abildgaard N, Pedersen PT, Hammerstrøm J, Laaksonen A,
Bazia P, et al: Autologous stem cell transplantation versus novel
drugs or conventional chemotherapy for patients with relapsed
multiple myeloma after previous ASCT. Bone Marrow Transplant.
50:808–812. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao X, Ji CY, Liu GQ, Ma DX, Ding HF, Xu
M and Xing J: Immunomodulatory effect of DC/CIK combined with
chemotherapy in multiple myeloma and the clinical efficacy. Int J
Clin Exp Pathol. 8:13146–13155. 2015.PubMed/NCBI
|
|
18
|
Palumbo A, Cavallo F, Gay F, Di Raimondo
F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C,
Ribakovsky E, et al: Autologous transplantation and maintenance
therapy in multiple myeloma. N Engl J Med. 371:895–905. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scott K, Hayden PJ, Will A, Wheatley K and
Coyne I: Bortezomib for the treatment of multiple myeloma. Cochrane
Database Syst Rev. 4:CD0108162016.PubMed/NCBI
|
|
20
|
Tabayashi T, Takahashi Y, Kimura Y,
Tomikawa T, Sagawa M, Nemoto T, Watanabe R, Tokuhira M, Mori S and
Kizaki M: Targeting the Wnt/β-catenin signaling pathway in multiple
myeloma: A possible new therapeutic approach to overcome
bortezomib-resistance. Blood. 124:33722014. View Article : Google Scholar
|
|
21
|
Jang GB, Kim JY, Cho SD, Park KS, Jung JY,
Lee HY, Hong IS and Nam JS: Blockade of Wnt/β-catenin signaling
suppresses breast cancer metastasis by inhibiting CSC-like
phenotype. Sci Rep. 5:124652015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim JY, Lee HY, Park KK, Choi YK, Nam JS
and Hong IS: CWP232228 targets liver cancer stem cells through
Wnt/β-catenin signaling: a novel therapeutic approach for liver
cancer treatment. Oncotarget. 7:20395–20409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q
and Chen J: PCDH10 inhibits cell proliferation of multiple myeloma
via the negative regulation of the Wnt/β-catenin/BCL-9 signaling
pathway. Oncol Rep. 34:747–754. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su N, Wang P and Li Y: Role of
Wnt/β-catenin pathway in inducing autophagy and apoptosis in
multiple myeloma cells. Oncol Lett. 12:4623–4629. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ashihara E, Takada T and Maekawa T:
Targeting the canonical Wnt/β-catenin pathway in hematological
malignancies. Cancer Sci. 106:665–671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pati ML, Vitale P, Ferorelli S, Iaselli M,
Miciaccia M, Boccarelli A, Di Mauro GD, Fortuna CG, Souza Domingos
TF, Rodrigues Pereira da Silva LC, et al: Translational impact of
novel widely pharmacological characterized mofezolac-derived COX-1
inhibitors combined with bortezomib on human multiple myeloma cell
lines viability. Eur J Med Chem. 164:59–76. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yin L, Kufe T, Avigan D and Kufe D:
Targeting MUC1-C is synergistic with bortezomib in downregulating
TIGAR and inducing ROS-mediated myeloma cell death. Blood.
123:2997–3006. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin Y, Xu L, Wu X, Feng J, Shu M, Gu H,
Gao G, Zhang J, Dong B and Chen X: Synergistic efficacy of the
demethylation agent decitabine in combination with the protease
inhibitor bortezomib for treating multiple myeloma through the
Wnt/β-catenin pathway. Oncol Res. 27:729–737. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang P, Zhao X, Zhang W, He A, Lei B,
Zhang W and Chen Y: Leukemia-associated gene MLAA-34 reduces
arsenic trioxide-induced apoptosis in HeLa cells via activation of
the Wnt/β-catenin signaling pathway. PLoS One. 12:e01868682017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chung J, Karkhanis V, Baiocchi RA and Sif
S: Protein arginine methyltransferase 5 (PRMT5) promotes survival
of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β
proliferative signaling. J Biol Chem. 294:7692–7710. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Walker MP, Stopford CM, Cederlund M, Fang
F, Jahn C, Rabinowitz AD, Goldfarb D, Graham DM, Yan F, Deal AM, et
al: FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B
cell lymphoma. Sci Signal. 8:ra12. 2015. View Article : Google Scholar : PubMed/NCBI
|
